Detailed price information for Glucotrack Inc (GCTK) from The Globe and Mail including charting and trades.
Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.
Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.
GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.
Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. The
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
GlucoTrack shares soar 80% after-hours as Lokahi Therapeutics signs first external glioblastoma licensing partnership with Innovate GBM.
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines (NASDAQ:GRML) shares
RUTHERFORD, N.J. & LA JOLLA, Calif., September 23, 2026--Lōkahi CEO Erik Emerson outlines LT-100 progress, ai² platform growth, and a strategy to discover, advance, and monetize assets.
Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.
RUTHERFORD, N.J. & LA JOLLA, Calif., September 11, 2026--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.
Detailed price information for Glucotrack Inc (GCTK-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Tipranks Press Release.
RUTHERFORD, N.J. & LA JOLLA, Calif., August 27, 2026--Glucotrack (Nasdaq: GCTK) announced a 1-for-15 reverse stock split effective August 31, 2026, to support Nasdaq listing compliance.
RUTHERFORD, N.J. & LA JOLLA, Calif., August 25, 2026--Lōkahi Therapeutics™ initiates GMP manufacturing of LT-100 and advances preparations for the program's next clinical milestone.
This is the newest page. Registered accounts read further back.